Section of Hepatobiliary-Pancreatic & Gastrointestinal Surgery

Medicine & Life Sciences

1. Abdominal Muscles 6%
2. Adenocarcinoma 94%
3. Apoptosis 11%
4. Bile Ducts 13%
5. Blood Vessels 6%
6. Caspases 13%
7. CD55 Antigens 10%
8. Cell Death 13%
9. Cell Line 6%
10. Cholangiocarcinoma 14%
11. Cholecystectomy 29%
12. Chronic Pancreatitis 6%
13. Colorectal Neoplasms 14%
14. Complement System Proteins 9%
15. Costs and Cost Analysis 10%
16. Databases 17%
17. Dendritic Cells 9%
18. Disease-Free Survival 7%
19. DNA 7%
20. Drug Therapy 13%
21. Erythrocytes 9%
22. Exonucleases 6%
23. Gallbladder 8%
24. Gallbladder Neoplasms 9%
25. Gastric Bypass 11%
26. Gastric Emptying 6%
27. gemcitabine 28%
28. Guidelines 16%
29. Hepatectomy 14%
30. Hepatocellular Carcinoma 8%
31. Herniorrhaphy 8%
32. human exonuclease 5 6%
33. Immunity 13%
34. Immunization 8%
35. Immunosuppressive Agents 6%
36. Immunotherapy 9%
37. Jaundice 8%
38. Klatskin Tumor 7%
39. Laparoscopic Cholecystectomy 21%
40. Length of Stay 11%
41. Ligands 26%
42. Liver 28%
43. Liver Neoplasms 11%
44. Lymph Node Ratio 8%
45. Lymph Nodes 16%
46. Macrophages 15%
47. Melanoma 8%
48. Membranes 9%
49. mesothelin 14%
50. Mitochondria 9%
51. Monocytes 11%
52. Morbidity 9%
53. Mortality 13%
54. Multivariate Analysis 8%
55. Myeloid-Derived Suppressor Cells 10%
56. Neck 6%
57. Neoadjuvant Therapy 14%
58. Neoplasm Metastasis 30%
59. Neoplasms 78%
60. Neuroendocrine Tumors 14%
61. Nomograms 6%
62. Operative Time 6%
63. Ovarian Neoplasms 13%
64. Oxaliplatin 8%
65. Pancreas 38%
66. Pancreatectomy 64%
67. Pancreatic Ducts 9%
68. Pancreatic Fistula 21%
69. Pancreatic Neoplasms 100%
70. Pancreaticoduodenectomy 72%
71. Patient Readmission 8%
72. Pharmaceutical Preparations 6%
73. Piperazine 7%
74. Portal Vein 9%
75. Postoperative Complications 7%
76. Practice Guidelines 11%
77. Propensity Score 6%
78. Prospective Studies 6%
79. Protein Deficiency 7%
80. Proteins 13%
81. Radiofrequency Ablation 11%
82. Radiotherapy 11%
83. Recurrence 18%
84. Residual Neoplasm 7%
85. Robotics 6%
86. Safety 6%
87. sigma-2 receptor 41%
88. Splenic Artery 7%
89. Splenic Vein 6%
90. Stomach 14%
91. Stomach Neoplasms 12%
92. Surgeons 21%
93. Survival 57%
94. SV119 18%
95. SW IV-134 21%
96. Swine 6%
97. T-Lymphocytes 16%
98. Therapeutics 20%
99. Vasculopathy, Retinal, With Cerebral Leukodystrophy 10%
100. Wounds and Injuries 11%